{"id":"hyml-122-cytarabine","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cytarabine is a nucleoside analog that inhibits DNA polymerase, thereby preventing DNA replication and cell division.","oneSentence":"inhibits DNA polymerase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:22:52.382Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT05241093","phase":"PHASE2","title":"A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Tarapeutics Science Inc.","startDate":"2022-03-29","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML)","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"HYML-122; cytarabine","genericName":"HYML-122; cytarabine","companyName":"Tarapeutics Science Inc.","companyId":"tarapeutics-science-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"inhibits DNA polymerase Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}